78 related articles for article (PubMed ID: 7865317)
1. Behavioral studies relevant to vaccine trial preparation: an introduction.
Turner CF; Sheon AR
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S273-6. PubMed ID: 7865317
[TBL] [Abstract][Full Text] [Related]
2. Behavioral research contributions to planning and conducting HIV vaccine efficacy studies.
Temoshok LR
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S277-80. PubMed ID: 7865318
[No Abstract] [Full Text] [Related]
3. Preparations for AIDS vaccine trials. Developing brief valid screening instruments for HIV-related sexual risk behavior among gay and bisexual men.
McKirnan DJ; Doetsch J; Vanable P; Buchbinder S; Douglas JM; Judson F
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S285-8. PubMed ID: 7865320
[TBL] [Abstract][Full Text] [Related]
4. Preparations for AIDS vaccine trials. Recruitment and retention of in- and out-of-treatment injection drug users.
Woody GE; Metzger D; Mulvaney F
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S197-9. PubMed ID: 7865300
[No Abstract] [Full Text] [Related]
5. Interest in HIV vaccines among injection drug users in Baltimore, Maryland.
Vlahov D; Astemborski J; Solomon L; Galai N; Basarab L; Nelson KE
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S265-8. PubMed ID: 7865315
[TBL] [Abstract][Full Text] [Related]
6. Participation of homosexual/bisexual men in preventive HIV vaccine trials: baseline attitudes and concerns and predicted behaviors during trials.
Douglas JM; Judson FN; Parks JP; Buchbinder S; McKirnan D
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S257-60. PubMed ID: 7865313
[No Abstract] [Full Text] [Related]
7. Cultural feasibility studies in preparation for clinical trials to reduce maternal-infant HIV transmission in Haiti.
Coreil J; Losikoff P; Pincu R; Mayard G; Ruff AJ; Hausler HP; Desormeau J; Davis H; Boulos R; Halsey NA
AIDS Educ Prev; 1998 Feb; 10(1):46-62. PubMed ID: 9505098
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and cohort development for HIV vaccine trials in Haiti.
Deschamps MM; Johnson WD; Pape JW
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S231-3. PubMed ID: 7865308
[TBL] [Abstract][Full Text] [Related]
9. The role of prevention research in HIV vaccine trials.
Vermund SH
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S303-5. PubMed ID: 7865326
[TBL] [Abstract][Full Text] [Related]
10. Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors.
Navaline HA; Snider EC; Petro CJ; Tobin D; Metzger D; Alterman AI; Woody GE
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S281-3. PubMed ID: 7865319
[TBL] [Abstract][Full Text] [Related]
11. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials.
Chesney MA; Lurie P; Coates TJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):30-5. PubMed ID: 7712232
[No Abstract] [Full Text] [Related]
12. The decision to enroll in HIV vaccine efficacy trials: concerns elicited from gay men at increased risk for HIV infection.
MacQueen KM; Buchbinder S; Douglas JM; Judson FN; McKirnan DJ; Bartholow B
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S261-4. PubMed ID: 7865314
[No Abstract] [Full Text] [Related]
13. HIV vaccine trials: critical issues in informed consent.
Lindegger G; Richter LM
S Afr J Sci; 2000 Jun; 96():313-7. PubMed ID: 15739286
[TBL] [Abstract][Full Text] [Related]
14. Preventive HIV type 1 vaccine clinical trials: a regulatory perspective.
Goldenthal KL; Vaillancourt JM; Geber A; Lucey DR
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S333-40. PubMed ID: 9814962
[TBL] [Abstract][Full Text] [Related]
15. Will preventive HIV vaccine efficacy trials be possible with female injection drug users?
Meyers K; Metzger DS; McLellan AT; Navaline H; Sheon AR; Woody GE
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):577-85. PubMed ID: 8548338
[TBL] [Abstract][Full Text] [Related]
16. Willingness to participate in HIV vaccine trials among HIV-negative gay men in Sydney, Australia.
Van de Ven P; Mao L; Crawford J; Prestage G; Grulich A; Kaldor J; Kippax S
Int J STD AIDS; 2005 Apr; 16(4):314-7. PubMed ID: 15899086
[TBL] [Abstract][Full Text] [Related]
17. Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention.
Allen M; Lau CY
Soc Sci Med; 2008 Feb; 66(4):945-51. PubMed ID: 18162272
[TBL] [Abstract][Full Text] [Related]
18. Domestic AIDS vaccine trials: addressing the potential for social harm to the subjects of human experiments.
Leider PA
Calif Law Rev; 2000; 88():1185-232. PubMed ID: 11067733
[TBL] [Abstract][Full Text] [Related]
19. The epidemiological contribution to the preparation of field trials for HIV and STI vaccines: objectives and methods of feasibility studies.
Suligoi B; Wagner TM; Ciccozzi M; Rezza G
Vaccine; 2005 Feb; 23(12):1437-45. PubMed ID: 15670878
[TBL] [Abstract][Full Text] [Related]
20. Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial.
Newman PA; Daley A; Halpenny R; Loutfy M
Vaccine; 2008 Feb; 26(8):1091-7. PubMed ID: 18237829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
